United Therapeutics
Stock Forecast, Prediction & Price Target

United Therapeutics (UTHR) stock Price Target by analysts

Last Year
Average Price Target

$419

Potential upside: 33.77%

Based on 3 analysts

United Therapeutics price prediction

Strike.market

What is United Therapeutics stock analysts` prediction?

United Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for United Therapeutics in the last 3 months, the avarage price target is $419, with a high forecast of $NaN. The average price target represents a 33.77% change from the last price of $313.22.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

United Therapeutics stock Price Target by analysts

Full breakdown of analysts given United Therapeutics price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Andrew Fein
H.C. Wainwright
0%
0/1
10 months ago $425 35.68% upside $361.4 StreetInsider
Previous targets (0)
Jasper Hellweg
Argus Research
0%
0/1
10 months ago $400 27.70% upside $362.36 TheFly
Previous targets (0)
Eun Yang
Jefferies
0%
0/1
12 months ago $432 37.92% upside $353 StreetInsider
Previous targets (0)
Hartaj Singh
Oppenheimer
0%
0/2
about 1 year ago $575 83.57% upside $362.45 StreetInsider
Previous targets (1)
Ashwani Verma
UBS
0%
0/1
about 1 year ago $370 18.12% upside $317.18 StreetInsider
Previous targets (0)
Tiago Fauth
Wells Fargo
0%
0/1
about 1 year ago $350 11.74% upside $275.76 TheFly
Previous targets (0)
Hartaj Singh
Oppenheimer
0%
0/2
over 1 year ago $400 27.70% upside $255.14 TheFly
Previous targets (1)
Chris Shibutani
Goldman Sachs
100%
1/1
over 1 year ago $215 -31.35% downside $214.74 Benzinga
Previous targets (0)
Unknown
Argus Research
N/A
over 2 years ago $300 -4.22% downside $263.41 Benzinga
N/A
Unknown
UBS
N/A
almost 3 years ago $320 2.16% upside $273.72 Benzinga
N/A
Unknown
Morgan Stanley
N/A
almost 3 years ago $330 5.35% upside $276.07 Benzinga
N/A
Unknown
Goldman Sachs
N/A
almost 3 years ago $230 -26.56% downside $278.55 Benzinga
N/A
Unknown
H.C. Wainwright
N/A
over 3 years ago $255 -18.58% downside $210.14 Benzinga
N/A
Unknown
Credit Suisse
N/A
over 3 years ago $247 -21.14% downside $210.14 Benzinga
N/A
Unknown
Jefferies
N/A
over 3 years ago $245 -21.78% downside $217.14 Benzinga
N/A
Unknown
J.P. Morgan
N/A
over 3 years ago $238 -24.01% downside $218 Benzinga
N/A
Unknown
J.P. Morgan
N/A
over 3 years ago $223 -28.80% downside $184.24 Benzinga
N/A
Tiago Fauth
Credit Suisse
100%
1/1
over 4 years ago $205 -34.55% downside $198.14 StreetInsider
Previous targets (0)

United Therapeutics Financial Estimates

United Therapeutics Revenue Estimates

United Therapeutics EBITDA Estimates

United Therapeutics Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$1.68B
 
N/A
$1.93B
 
14.87%
$2.32B
 
20.20%
Avg: $2.96B
Low: $2.72B
High: $3.29B
avg. 27.57%
Avg: $3.16B
Low: $2.92B
High: $3.46B
avg. 6.46%
Avg: $3.29B
Low: $3.04B
High: $3.61B
avg. 4.33%
Avg: $3.41B
Low: $3.15B
High: $3.73B
avg. 3.48%
Net Income
 
% change YoY
$475.8M
 
N/A
$727.3M
 
52.85%
$984.8M
 
35.40%
Avg: $1.29B
Low: $1.07B
High: $1.87B
avg. 31.78%
Avg: $1.31B
Low: $840.42M
High: $1.56B
avg. 1.16%
Avg: $1.47B
Low: $1.33B
High: $1.65B
avg. 12.50%
Avg: $1.70B
Low: $1.53B
High: $1.91B
avg. 15.64%
EBITDA
 
% change YoY
$614.8M
 
N/A
$984.7M
 
60.16%
$1.38B
 
40.83%
Avg: $1.09B
Low: $1.00B
High: $1.21B
avg. -21.27%
Avg: $1.16B
Low: $1.07B
High: $1.27B
avg. 6.46%
Avg: $1.21B
Low: $1.12B
High: $1.32B
avg. 4.33%
Avg: $1.25B
Low: $1.16B
High: $1.37B
avg. 3.48%
EPS
 
% change YoY
$10.6
 
N/A
$15.98
 
50.75%
$21.04
 
31.66%
Avg: $26.94
Low: $21.67
High: $37.65
avg. 28.06%
Avg: $26.93
Low: $16.91
High: $31.41
avg. -0.05%
Avg: $29.72
Low: $26.79
High: $33.37
avg. 10.35%
Avg: $34.37
Low: $30.99
High: $38.59
avg. 15.64%
Operating Expenses
 
% change YoY
$1.00B
 
N/A
$809.9M
 
-19.58%
$885.1M
 
9.28%
Avg: $743.17M
Low: $683.20M
High: $824.01M
avg. -16.03%
Avg: $791.22M
Low: $731.29M
High: $866.03M
avg. 6.46%
Avg: $825.53M
Low: $763.01M
High: $903.58M
avg. 4.33%
Avg: $854.30M
Low: $789.59M
High: $935.07M
avg. 3.48%

FAQ

What is United Therapeutics stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 15.27% in 2025-2028.

We have gathered data from 12 analysts. Their low estimate is 1.07B, average is 1.29B and high is 1.87B.

What is United Therapeutics stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 10.46% in 2025-2028.

We have gathered data from 11 analysts. Their low revenue estimate is $2.72B, average is $2.96B and high is $3.29B.

What is United Therapeutics stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 13.50% in 2025-2028.

We have gathered data from 12 analysts. Their low earnings per share estimate is $21.67, average is $26.94 and high is $37.65.

What is the best performing analyst?

In the last twelve months 3 analysts have been covering United Therapeutics stock. The most successful analyst is Andrew Fein.